Fig. 3

ROC AUC for circN4BP2L2, CA125 and HE4 in type I EOC with regard to tumor stage. It contains ROC AUC for circN4BP2L2 comparing early-stage type I EOC with benign (a) and normal (b) cohorts; ROC AUC for circN4BP2L2 comparing late-stage type I EOC with benign (c) and normal (d) cohorts; ROC AUC for CA125 comparing early-stage type I EOC with benign (e) and normal (f) cohorts; ROC AUC for CA125 comparing late-stage type I EOC with benign (g) and normal (h) cohorts; ROC AUC for HE4 comparing early-stage type I EOC with benign (i) and normal (j) cohorts; and ROC AUC for HE4 comparing late-stage type I EOC with benign (k) and normal (l) cohorts